HIV drug resistance report 2021
HIV drug resistance (HIVDR) can compromise the effectiveness of antiretroviral therapy (ART) in reducing HIV incidence and HIV-associated morbidity and mortality. Minimizing the spread of HIVDR is a critical aspect of the broader global response to antimicrobial resistance. WHO recommends that countries routinely implement nationally representative HIVDR surveys. The WHO HIV drug resistance report 2021 shows substantial progress in the implementation of HIVDR surveillance. Between 2014 and 2021, 56 countries implemented HIVDR surveys using WHO-recommended methods. The HIV drug resistance report 2021 summarizes findings from 38 countries that had finalized the surveys by the time of this report and shared data with WHO.
- Report on the global action plan on HIV drug resistance 2017–2021
- Unequal, unprepared, under threat: why bold action against inequalities is needed to end AIDS, stop COVID-19 and prepare for future pandemics
- Antimicrobial resistance and water: the risks and costs for economies and societies
- Guidance for the surveillance of drug resistance in tuberculosis: Sixth edition